Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus RENESE R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus RENESE R.
DEMI-REGROTON vs RENESE-R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination